While one study found lower rates of preterm birth alongside higher rates of hypertensive disorders, another found fewer ...

GLP-1 Receptor Agonist Market. The global GLP-1 receptor agonist market is on the verge of unprecedented growth, fueled by ...

Risk of suicidality wasn't higher for type 2 diabetes patients starting on GLP-1 receptor agonists than for those on two other popular classes of diabetes drugs, a U.K. cohort study found. In fully ...

Use of GLP-1 receptor agonists to treat type 2 diabetes is not associated with an increased risk of suicidality compared with ...

Evidence suggests no increased risk The use of glucagon-like peptide-1 (GLP-1) receptor agonists has surged in recent years, driven by their benefits in glucose control in type 2 diabetes, weight ...

“The thing most amazing about them is how these drugs suddenly alter the dopamine-related reward pathway in the brain making us less of a slave to cravings. Today, 73% of Americans are obese or ...

A study comparing GLP-1 users to others on antidiabetic drugs showed no added risk once confounders were accounted for.

The Company granted Mr. Gengos a new hire option to purchase 750,000 shares of Terns common stock. The option has a 10-year term and an exercise price per share equal to $3.73, which was the closing ...

The MHRA reveals a staggering rise in deaths linked to weight loss and diabetes medications in the UK, with concerns over ...

Eikon’s lead candidate EIK1001 is being investigated for melanoma in combination with MSD’s Keytruda in a Phase III trial.

For individuals with type 2 diabetes (T2D), semaglutide is associated with a modestly increased risk for nonarterit ...

Obesity and diabetes have been two of the greatest public health challenges for decades. Many different diets and fads have promised the public ...